

METRICS: Access to Medicines



Independently assured metric by

Apex

| Category/metric | FY20 Data | FY21 Data | FY22 Data | |
|---|---------------------|-----------|-----------|-------------------------------------|
| Access to Medicines | | | | |
| Number of patients in LMICs and countries with evolving healthcare systems who have received access to Takeda's medicines and vaccines through Takeda-sponsored and -supported clinical trials ¹ | 70,000 ² | 6,430 | 7,369 | <input checked="" type="checkbox"/> |
| Access to Medicines Programs in Low- and Middle- Income Countries and Evolving Healthcare Systems (Affordability-based Patient Assistance Programs) ^{3,4} | 740 | 983 | 1,366 | |
| Access to Medicines Programs in Low- and Middle- Income Countries and Evolving Healthcare Systems (Charitable Assistance Programs) ⁵ | 143 | 160 | 189 | <input checked="" type="checkbox"/> |
| Number of countries our Access to Medicines programs operate in ⁶ | 36 | 39 | 44 | <input checked="" type="checkbox"/> |

¹ Patients enrolled in clinical trials, clinical research and clinical collaborative research studies in Low Income Countries (LICs), Low & Middle Income Countries (LMICs) and Upper Middle Income Countries (UMICs), per World Bank definitions, during the fiscal year.

² Increase in FY20 figure related to participation in clinical studies for Takeda's TAK-003

³ Affordability-based Patient Assistance Programs are programs customized for specific country and product combinations. Enrolment is subject to both individual means-testing to evaluate a patient's ability to pay for treatment and medical eligibility criteria. Newly enrolled patients over the fiscal year are reported as patients who have received treatment.

⁴ This is one of our corporate philosophy metrics; "Access to Medicines Programs in Low- and Middle- Income Countries and Evolving Healthcare Systems." Assurance statement and more details are available [here](#).

⁵ Charitable Access Programs are structured free of charge programs with an NGO partner.

⁶ Countries with affordability-based Patient Assistance Programs and active patients enrolled in a Charitable Access Program. Country numbers will fluctuate year over year as patient needs evolve (i.e., levels of reimbursement, new product availability).